A FibroScan® based risk stratification strategy can reduce liver disease diagnosis and management costs, resulting in a better allocation of resources.
As part of an overall care management plan, FibroScan® examinations can lead to reduced costs, improved outcomes, and improved patient satisfaction. Care delivery models featuring FibroScan® are currently in practice or in development.
NASHNet hospital systems have already started to generate real world evidence to support FibroScan® based platforms to more efficiently and effectively identify and manage patients with fibrotic-NASH in the hospital setting.
FibroScan® enhances population health management by improving diagnosis accuracy at the point of care to allow for better accounting for health risks among the populations served.
FibroScan® devices are FDA cleared as an aid to diagnose and monitor adult patients with liver disease, as part of an overall assessment of the liver. FibroScan® devices utilize proprietary VCTE™, which applies a mechanically induced shear wave and does not utilize diagnostic imaging.
Yes, testing billed under CPT category 1 code 91200 is specific to the FibroScan® examination.
Hospital outpatient clinics performing the FibroScan® examination should bill 91200. Coverage and payment of FibroScan® examination may vary by commercial payers.
The physician charging for test interpretation and reporting will bill 91200-26 which is 0.40 RVU. Coverage and payment for FibroScan® examination may vary by commercial payers.
Echosens maintains a Reimbursement Hotline at (866) 905-4837, option number 4.
Yes, category 1 CPT code 91200 is specific to the FibroScan® examination.
Physician offices performing the FibroScan® examination should bill 91200. Coverage and payment of a FibroScan® examination may vary by commercial payers.
Echosens maintains a Reimbursement Hotline at 866-905-4837, option number 4.